

Martin Busch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6171017/publications.pdf>

Version: 2024-02-01

25
papers

918
citations

567144

15
h-index

501076

28
g-index

32
all docs

32
docs citations

32
times ranked

1707
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, , .	2.1	0
2	Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases. <i>Diagnostics</i> , 2022, 12, 67.	1.3	2
3	Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages â€” A Follow-up Analysis of Health Insurance Data from Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 821-830.	0.6	4
4	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 277-283.	1.4	1
5	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.4	39
6	Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. <i>Transplantation Proceedings</i> , 2021, 53, 1454-1461.	0.3	8
7	Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. <i>Journal of Internal Medicine</i> , 2021, 290, 1219-1232.	2.7	27
8	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 886.	1.0	15
9	Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 661-677.	2.3	24
10	FP155PREDICTORS OF RENAL INVOLVEMENT IN ANCA ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i81-i82.	0.4	0
11	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. <i>PLoS ONE</i> , 2018, 13, e0202604.	1.1	20
12	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease â€” cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. <i>BMC Nephrology</i> , 2016, 17, 59.	0.8	18
13	Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 441-451.	0.4	132
14	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. <i>Kidney International</i> , 2015, 88, 1411-1418.	2.6	23
15	Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study. <i>PLoS ONE</i> , 2015, 10, e0122552.	1.1	18
16	Rituximab for the second- and thirdline therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. <i>Clinical Nephrology</i> , 2013, 80, 105-113.	0.4	13
17	Advanced Glycation End Products and Î²₂-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients. <i>Blood Purification</i> , 2012, 34, 3-9.	0.9	9
18	The German Chronic Kidney Disease (GCKD) study: design and methods. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1454-1460.	0.4	127

#	ARTICLE	IF	CITATIONS
19	Advanced glycation end products and the kidney. <i>European Journal of Clinical Investigation</i> , 2010, 40, 742-755.	1.7	184
20	Vitamin B ₆ ; Metabolism in Chronic Kidney Disease – Relation to Transsulfuration, Advanced Glycation and Cardiovascular Disease. <i>Nephron Clinical Practice</i> , 2010, 114, c38-c46.	2.3	24
21	Serum Levels of the Advanced Glycation End Products N ^ε -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension. <i>Nephron Clinical Practice</i> , 2008, 108, c291-c297.	2.3	18
22	The Advanced Glycation End Product N ^ε -Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension. <i>American Journal of Kidney Diseases</i> , 2006, 48, 571-579.	2.1	59
23	Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. <i>Kidney International</i> , 2004, 66, 338-347.	2.6	108
24	Are advanced glycation end products cardiovascular risk factors in patients with CRF?. <i>American Journal of Kidney Diseases</i> , 2003, 41, S52-S56.	2.1	29
25	Validated capillary gas chromatographic mass spectrometric assay to determine 2-methylcitric acid I and II levels in human serum by using a pulsed splitless injection procedure. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 775, 215-223.	1.2	6